> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Real-world immune checkpoint inhibitor survival is often poorer than in pivotal trials
- URL: https://www.coios.me/real-world-immune-checkpoint-inhibitor-survival-is-often/
- Published: 2026-11-08T13:08:29.000Z
- Updated: 2026-11-08T14:08:30.000Z
- Description: Of 2,514 Belgian metastatic patients on immune checkpoint inhibitors, 568 stopped without further therapy and survived a median 21.4 months.
- Author: Daniel Ryan
- Tags: Health today, Cancer, Belgium, #preprint, #refines, #item, #source-2026-11, #score-68

This retrospective cohort study followed 3,231 adults given immune checkpoint inhibitors at four Belgian hospitals. Structured and free-text health records were harmonised with the OMOP common data model and natural language processing. Of 2,514 with metastatic disease, 568 (22.6%) stopped without further therapy, surviving a median 21.4 months. Melanoma median survival was 78 months, time on treatment 7 and time to next treatment 26\. ECOG performance status of 2 or more was associated with poorer survival than 0-1 (adjusted HR 2.18, 95% CI 1.82-2.60). Real-world survival was often poorer than in pivotal trials, but this comparison was descriptive only.

*Why it is interesting: Some patients survived for long periods after stopping immunotherapy without further treatment. In lung cancer treated with pembrolizumab plus chemotherapy, survival with ECOG 0-1 came closer to trial results than with ECOG 2 or more.*

Source

[medRxiv, 3 November 2026](https://doi.org/10.64898/2026.11.02.26367076?ref=coios.me)

Paper

Comprehensive real-world utilization, treatment trajectories, and outcomes of immune checkpoint inhibitors across cancer types: the multicenter FAIR-ICI cohort

Authors

Ha LT, Donck FV, Bassez I, Oeste CL, Vulsteke C, Delombaerde D et al.

DOI

10.64898/2026.11.02.26367076

Type

Preprint

Design

Retrospective multicentre EHR cohort, four Belgian hospitals, 3,231 adults treated with immune checkpoint inhibitors; OMOP-CDM harmonisation and NLP; years not stated

Verdict

Refines prior evidence

Driver

[Cancer](https://www.coios.me/d-cancer/)